A report from the Scottish Public Services Ombudsman (SPSO) has detailed a case where a patient died weeks after a family doctor failed to recognize and escalate symptoms of pancreatic cancer. The watchdog stated that there were missed opportunities to identify the significance of the patient's symptoms, which resulted in an "unreasonable delay" in diagnosis and inadequate end-of-life care.
The unnamed patient initially presented with unexplained weight loss and was diagnosed with diabetes. Despite continuing to experience symptoms, including further weight loss, the condition was not initially suspected to be cancer. The SPSO investigation found that "red flag symptoms of pancreatic cancer" were present from the patient's first contact with the practice.
Pancreatic cancer is one of the deadliest forms of the disease, with approximately three-quarters of diagnosed individuals dying within a year. It is often diagnosed at a late stage due to vague early symptoms, making timely diagnosis crucial. Health officials emphasize that early warning signs such as unexplained weight loss, fatigue, nausea, and abdominal pain should not be overlooked.
After months of suffering, the patient eventually asked their doctor about the possibility of pancreatic cancer. They were subsequently referred to gastroenterology specialists, and blood tests later confirmed the diagnosis. The patient died just six weeks later.
The SPSO criticized the GP's "unreasonable reliance on telephone consultations," suggesting it may have contributed to the diagnostic delay. The medical practice involved has been ordered to apologize to the patient's family for the "unreasonable delay in recognizing specific symptoms" indicative of cancer.
Pancreatic cancer rates have increased by approximately 17% in Britain since the 1990s, with factors such as rising obesity rates and environmental influences thought to be contributing. Smoking, obesity, consumption of processed meats, and alcohol are known risk factors for the disease. While symptoms can include jaundice, itchy skin, and dark urine, they often overlap with other conditions, making early detection challenging.
Recent medical advancements offer some hope for improved outcomes. A drug called daraxonrasib has shown potential to double the life expectancy of pancreatic cancer patients without disease progression, a development described by experts as "landscape changing." Findings for this drug have been submitted to U.S. regulators, with an application to UK regulators expected to follow.